MCID: ACR007
MIFTS: 70

Acromegaly

Categories: Endocrine diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Acromegaly

MalaCards integrated aliases for Acromegaly:

Name: Acromegaly 12 77 54 60 38 13 56 45 15 17 74
Growth Hormone Excess 54 30
Growth Hormone-Secreting Pituitary Adenoma 74
Somatotroph Adenoma 54
Pituitary Giant 54

Characteristics:

Orphanet epidemiological data:

60
acromegaly
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (Worldwide),1-9/100000 (Worldwide),1-9/100000 (Spain),1-9/100000 (Italy),1-9/100000 (United Kingdom),1-9/1000000 (Belgium),1-9/100000 (Belgium),1-5/10000 (Germany),1-9/100000 (Croatia),1-9/1000000 (Ireland),1-9/100000 (Ireland),1-9/1000000 (Finland),1-9/1000000 (Korea, Republic of),1-9/100000 (Korea, Republic of),1-9/1000000 (Iceland),1-5/10000 (Iceland); Age of onset: Adult;

Classifications:



Summaries for Acromegaly

NIH Rare Diseases : 54 Acromegaly is a hormonal disorder that results from the pituitary gland producing too much growth hormone (GH). It is most often diagnosed in middle-aged adults, although symptoms can appear at any age. Signs and symptoms include abnormal growth and swelling of the hands and feet; bone changes that; alter various facial features; arthritis; carpal tunnel syndrome; enlargement of body organs; and various other symptoms. The condition is usually caused by benign tumors on the pituitary called adenomas. Rarely, it is caused by tumors of the pancreas, lungs, and other parts of the brain stimulating the pituitary gland to produce GH. It is sporadic in 95% of the cases, but almost 50% of the childhood-onset cases have an identifiable genemutation, most commonly in the AIP gene or GPR101 gene. Treatment may include hormones, radiotherapy, and surgery. When left untreated, it can result in serious illness and premature death. When GH-producing tumors occur in childhood, the disease that results is called gigantism rather than acromegaly.   Acromegaly may also be part of other genetic syndromes such as multiple endocrine neoplasia syndrome type 1 and type 4, hereditary paraganglioma-pheochromocytoma syndrome, McCune-Allright syndrome, neurofibromatosis or Carney complex. 

MalaCards based summary : Acromegaly, also known as growth hormone excess, is related to pituitary adenoma 1, multiple types and growth hormone secreting pituitary adenoma. An important gene associated with Acromegaly is AIP (Aryl Hydrocarbon Receptor Interacting Protein), and among its related pathways/superpathways are Signaling by GPCR and Metabolism of proteins. The drugs Pasireotide and Octreotide have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and thyroid, and related phenotypes are osteoarthritis and hyperhidrosis

Disease Ontology : 12 A disease of metabolism that has material basis in excessive growth hormone production which results in enlargement located in limb.

Wikipedia : 77 Acromegaly is a disorder that results from excess growth hormone (GH) after the growth plates have... more...

Related Diseases for Acromegaly

Diseases related to Acromegaly via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 pituitary adenoma 1, multiple types 33.5 AIP GH1 IGF1 IGFBP3 PRL SST
2 growth hormone secreting pituitary adenoma 32.5 AIP GNAS PRL SST SSTR2
3 gigantism 32.5 AIP GH1 GHRH GPR101 PRL
4 pituitary tumors 31.0 AIP GH1 GNAS IGF1 MEN1 POMC
5 sleep apnea 30.9 GHRL IGF1 INS
6 pituitary apoplexy 30.9 AIP INS POMC PRL
7 mccune-albright syndrome 30.8 GH1 GNAS IGF1 PRL SST
8 growth hormone deficiency 30.8 GH1 GHRH GHRL IGF1 IGFBP3
9 galactorrhea 30.8 IGF1 PRL
10 bronchial adenomas/carcinoids childhood 30.7 POMC SST
11 dwarfism 30.6 GH1 GHR GHRH
12 fibrous dysplasia 30.5 GH1 GNAS IGF1 PRL SST
13 glucose intolerance 30.5 GHRL IGF1 IGFBP1 INS
14 amenorrhea 30.4 POMC PRL TRH
15 hyperprolactinemia 30.4 GH1 IGF1 POMC PRL SST TRH
16 fibrous dysplasia/mccune-albright syndrome 30.4 GH1 PRL
17 pituitary carcinoma 30.4 POMC PRL SST
18 acanthosis nigricans 30.3 IGF1 INS PRL
19 diabetes insipidus 30.3 INS POMC PRL
20 hypopituitarism 30.3 GH1 GHRH IGF1 IGFBP3 INS POMC
21 carcinoid syndrome 30.3 GHRH IGF1 MEN1 SST
22 pituitary infarct 30.2 IGF1 POMC PRL SST
23 empty sella syndrome 30.2 GH1 IGF1 POMC PRL TRH
24 pituitary adenoma, prolactin-secreting 30.2 AIP GH1 GNAS IGF1 MEN1 POMC
25 polycystic ovary syndrome 30.2 IGF1 IGFBP1 INS PRL
26 nelson syndrome 30.1 POMC PRL SST
27 microvascular complications of diabetes 1 30.1 IGF1 IGFBP3 INS SST
28 diabetes mellitus 30.1 GHRL IGF1 IGFBP1 INS MEN1 SST
29 insulin-like growth factor i 30.0 GH1 GHR GHRH IGF1 IGF2 IGFBP1
30 ovarian disease 30.0 IGF1 IGFBP1 INS PRL
31 isolated growth hormone deficiency 30.0 GH1 GHR GHRH IGF1
32 acidophil adenoma 30.0 IGF1 POMC SST
33 diabetes mellitus, noninsulin-dependent 29.9 GH1 GHRL IGF1 IGF2 IGFBP1 IGFBP3
34 lymphocytic hypophysitis 29.9 GH1 POMC
35 hyperthyroidism 29.9 GH1 GHRL GNAS INS PRL SST
36 pituitary hormone deficiency, combined, 2 29.9 GH1 GHR IGF1 POMC PRL
37 hypothyroidism 29.9 GH1 GNAS IGF1 IGFBP3 POMC PRL
38 conn's syndrome 29.8 GH1 GNAS MEN1 POMC PRL SST
39 neuroendocrine tumor 29.8 MEN1 SST SSTR2
40 diffuse idiopathic skeletal hyperostosis 29.8 IGF1 IGFBP3
41 hypothalamic disease 29.8 GH1 GHRH POMC PRL
42 craniopharyngioma 29.8 GH1 GHRL IGF1 INS PRL TRH
43 chronic kidney failure 29.7 IGF1 IGFBP1 IGFBP3 INS
44 turner syndrome 29.7 GH1 GHR IGF1 IGFBP1 IGFBP3
45 zollinger-ellison syndrome 29.7 GHRH MEN1 SST
46 chromophobe adenoma 29.7 GH1 GHRH INS POMC PRL TRH
47 islet cell tumor 29.6 IGF2 INS MEN1 SST
48 adenoma 29.6 AIP GH1 GNAS GPR101 IGF1 MEN1
49 glucose metabolism disease 29.6 GHRL IGF1 INS POMC SST
50 hyperinsulinism 29.6 GH1 GHRL IGF1 IGFBP1 IGFBP3 INS

Graphical network of the top 20 diseases related to Acromegaly:



Diseases related to Acromegaly

Symptoms & Phenotypes for Acromegaly

Human phenotypes related to Acromegaly:

60 33 (show top 50) (show all 62)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteoarthritis 60 33 hallmark (90%) Very frequent (99-80%) HP:0002758
2 hyperhidrosis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000975
3 macroglossia 60 33 hallmark (90%) Very frequent (99-80%) HP:0000158
4 coarse facial features 60 33 hallmark (90%) Very frequent (99-80%) HP:0000280
5 mandibular prognathia 60 33 hallmark (90%) Very frequent (99-80%) HP:0000303
6 macrotia 60 33 hallmark (90%) Very frequent (99-80%) HP:0000400
7 fatigue 60 33 hallmark (90%) Very frequent (99-80%) HP:0012378
8 joint swelling 60 33 hallmark (90%) Very frequent (99-80%) HP:0001386
9 arthralgia 60 33 hallmark (90%) Very frequent (99-80%) HP:0002829
10 full cheeks 60 33 hallmark (90%) Very frequent (99-80%) HP:0000293
11 thick lower lip vermilion 60 33 hallmark (90%) Very frequent (99-80%) HP:0000179
12 anterior hypopituitarism 60 33 hallmark (90%) Very frequent (99-80%) HP:0000830
13 broad forehead 60 33 hallmark (90%) Very frequent (99-80%) HP:0000337
14 long face 60 33 hallmark (90%) Very frequent (99-80%) HP:0000276
15 growth hormone excess 60 33 hallmark (90%) Very frequent (99-80%) HP:0000845
16 pituitary growth hormone cell adenoma 60 33 hallmark (90%) Very frequent (99-80%) HP:0011760
17 long penis 60 33 hallmark (90%) Very frequent (99-80%) HP:0000040
18 wide nose 60 33 hallmark (90%) Very frequent (99-80%) HP:0000445
19 large hands 60 33 hallmark (90%) Very frequent (99-80%) HP:0001176
20 tapered finger 60 33 hallmark (90%) Very frequent (99-80%) HP:0001182
21 tall stature 60 33 hallmark (90%) Very frequent (99-80%) HP:0000098
22 macrodactyly 60 33 hallmark (90%) Very frequent (99-80%) HP:0004099
23 broad foot 60 33 hallmark (90%) Very frequent (99-80%) HP:0001769
24 deep plantar creases 60 33 hallmark (90%) Very frequent (99-80%) HP:0001869
25 cortical diaphyseal thickening of the upper limbs 60 33 hallmark (90%) Very frequent (99-80%) HP:0003859
26 deep palmar crease 60 33 hallmark (90%) Very frequent (99-80%) HP:0006191
27 frontal bossing 60 33 frequent (33%) Frequent (79-30%) HP:0002007
28 depressivity 60 33 frequent (33%) Frequent (79-30%) HP:0000716
29 diabetes mellitus 60 33 frequent (33%) Frequent (79-30%) HP:0000819
30 hypertension 60 33 frequent (33%) Frequent (79-30%) HP:0000822
31 kyphosis 60 33 frequent (33%) Frequent (79-30%) HP:0002808
32 sleep apnea 60 33 frequent (33%) Frequent (79-30%) HP:0010535
33 widely spaced teeth 60 33 frequent (33%) Frequent (79-30%) HP:0000687
34 generalized hirsutism 60 33 frequent (33%) Frequent (79-30%) HP:0002230
35 anxiety 60 33 frequent (33%) Frequent (79-30%) HP:0000739
36 hypogonadotrophic hypogonadism 60 33 frequent (33%) Frequent (79-30%) HP:0000044
37 migraine 60 33 frequent (33%) Frequent (79-30%) HP:0002076
38 paresthesia 60 33 frequent (33%) Frequent (79-30%) HP:0003401
39 palpebral edema 60 33 frequent (33%) Frequent (79-30%) HP:0100540
40 spinal canal stenosis 60 33 frequent (33%) Frequent (79-30%) HP:0003416
41 hoarse voice 60 33 frequent (33%) Frequent (79-30%) HP:0001609
42 cerebral palsy 60 33 frequent (33%) Frequent (79-30%) HP:0100021
43 synophrys 60 33 frequent (33%) Frequent (79-30%) HP:0000664
44 abnormal toenail morphology 60 33 frequent (33%) Frequent (79-30%) HP:0008388
45 broad jaw 60 33 frequent (33%) Frequent (79-30%) HP:0012802
46 dysmenorrhea 60 33 frequent (33%) Frequent (79-30%) HP:0100607
47 abnormal fingernail morphology 33 frequent (33%) HP:0001231
48 hypertrophic cardiomyopathy 60 33 occasional (7.5%) Occasional (29-5%) HP:0001639
49 acanthosis nigricans 60 33 occasional (7.5%) Occasional (29-5%) HP:0000956
50 acne 60 33 occasional (7.5%) Occasional (29-5%) HP:0001061

GenomeRNAi Phenotypes related to Acromegaly according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 GHR GHRL GNAS IGF1 IGF2 IGFBP3

MGI Mouse Phenotypes related to Acromegaly:

47 (show all 12)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 AIP GHR GHRH GHRL GNAS IGF1
2 endocrine/exocrine gland MP:0005379 10.3 AIP GHR GHRH GHRL GNAS IGF1
3 growth/size/body region MP:0005378 10.25 AIP GHR GHRH GNAS IGF1 IGF2
4 behavior/neurological MP:0005386 10.24 GHR GHRL GNAS IGF2 IGFBP3 INS
5 cardiovascular system MP:0005385 10.18 AIP GHR GNAS GPR101 IGF1 IGF2
6 immune system MP:0005387 10.11 GHR GHRH GNAS IGF1 IGF2 IGFBP1
7 adipose tissue MP:0005375 10.05 GHR GHRL GNAS IGF1 IGFBP3 INS
8 liver/biliary system MP:0005370 10 AIP GHR GHRH GNAS IGF2 IGFBP1
9 integument MP:0010771 9.97 AIP GHR GNAS IGF1 IGF2 IGFBP3
10 nervous system MP:0003631 9.77 GHR GHRH GNAS IGF1 IGF2 INS
11 neoplasm MP:0002006 9.63 AIP GNAS IGF1 MEN1 POMC PRL
12 renal/urinary system MP:0005367 9.1 GHR GNAS IGF1 IGF2 INS POMC

Drugs & Therapeutics for Acromegaly

Drugs for Acromegaly (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 118)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pasireotide Approved Phase 4,Phase 3,Phase 2,Phase 1 396091-73-9 9941444
2
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 6400441 383414
3
lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 108736-35-2
4
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
5
Mecasermin Approved, Investigational Phase 4,Phase 3,Not Applicable 68562-41-4
6
Dopamine Approved Phase 4,Phase 3,Phase 2 62-31-7, 51-61-6 681
7
Cabergoline Approved Phase 4,Phase 3 81409-90-7 54746
8
Liraglutide Approved Phase 4 204656-20-2 44147092
9
Metformin Approved Phase 4 657-24-9 14219 4091
10
Zinc Approved, Investigational Phase 4 7440-66-6 32051
11
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-88-6, 585-86-4 493591
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Mitogens Phase 4,Phase 3,Phase 2,Not Applicable
16 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 insulin Phase 4,Phase 3,Phase 2,Not Applicable
18 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2,Not Applicable
21 Incretins Phase 4,Not Applicable
22 Liver Extracts Phase 4
23 Protective Agents Phase 4,Phase 2
24 Dopamine Agents Phase 4,Phase 3,Phase 2
25 Antiparkinson Agents Phase 4,Phase 3
26 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
27 Cardiotonic Agents Phase 4,Phase 2
28 Dopamine agonists Phase 4,Phase 3
29 Autonomic Agents Phase 4,Phase 2
30 Peripheral Nervous System Agents Phase 4,Phase 2
31 Sympathomimetics Phase 4,Phase 2
32 Hypoglycemic Agents Phase 4,Phase 2,Not Applicable
33 Sitagliptin Phosphate Phase 4
34 Dipeptidyl-Peptidase IV Inhibitors Phase 4
35
protease inhibitors Phase 4
36 HIV Protease Inhibitors Phase 4
37
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
38 Pharmaceutical Solutions Phase 3
39 Complement Factor I Phase 3,Not Applicable
40 Carboxymethylcellulose Sodium Phase 3
41 Radiopharmaceuticals Phase 3
42 Edotreotide Phase 3
43
Sodium Citrate Approved, Investigational Phase 2,Not Applicable 68-04-2
44
Histamine Approved, Investigational Phase 2 51-45-6 774
45
Dimenhydrinate Approved Phase 2 523-87-5 441281
46
Tadalafil Approved, Investigational Phase 2 171596-29-5 110635
47
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Not Applicable 77-92-9 311
48
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
49
Enclomiphene Investigational Phase 2 15690-57-0
50 Ethinyl estradiol, levonorgestrel drug combination Phase 2

Interventional clinical trials:

(show top 50) (show all 171)
# Name Status NCT ID Phase Drugs
1 Pasireotide LAR and Pegvisomant Study in Acromegaly Unknown status NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
2 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
3 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
4 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
5 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
6 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
7 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
8 Ultrasound Guided Octreotide LAR Injection in Acromegaly Completed NCT00552071 Phase 4 Octreotide LAR 30 MG Injection
9 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
10 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
11 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
12 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
13 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
14 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
15 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
16 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
17 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
18 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
19 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
20 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
21 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
22 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
23 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
24 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
25 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
26 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
27 Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues Completed NCT02354508 Phase 3 Pasireotide LAR
28 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
29 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
30 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide;octreotide LAR 30mg;lanreotide ATG 120mg
31 Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly Completed NCT00225979 Phase 3 Octreotide LAR
32 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
33 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)
34 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
35 Long Term Study With B2036-PEG Completed NCT00143416 Phase 3 Pegvisomant
36 Efficacy/Safety of Octreotide Acetate in Patients With Uncontrolled Acromegaly Completed NCT00372697 Phase 3 Octreotide acetate 30 mg suspension
37 Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly Completed NCT00444873 Phase 3 lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval
38 Safety and Efficacy of Octreotide Long Acting Release (LAR) in Treatment Naïve Acromegalic Patients Completed NCT00128232 Phase 3 Octreotide LAR
39 Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed NCT00383708 Phase 3 lanreotide (Autogel formulation);Pegvisomant
40 Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly Completed NCT00234572 Phase 2, Phase 3 Lanreotide (Autogel formulation)
41 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
42 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
43 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
44 A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed NCT00017927 Phase 3 Pegvisomant
45 Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients Completed NCT00210457 Phase 3 Lanreotide (Autogel formulation)
46 Strict IGF-1 Control in Acromegaly Recruiting NCT02952885 Phase 3 Pegvisomant
47 Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly Recruiting NCT02685709 Phase 3 Octreotide capsules;Injectable Somatostatin Analogs (octreotide or lanreotide);Cabergoline
48 Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess Recruiting NCT03882034 Phase 3 Pegvisomant
49 Ga-68-DOTATOC -PET in the Management of Pituitary Tumours Recruiting NCT02419664 Phase 3
50 Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly Active, not recruiting NCT03252353 Phase 3 octreotide capsules;Matching placebo

Search NIH Clinical Center for Acromegaly

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: acromegaly

Genetic Tests for Acromegaly

Genetic tests related to Acromegaly:

# Genetic test Affiliating Genes
1 Growth Hormone Excess 30

Anatomical Context for Acromegaly

MalaCards organs/tissues related to Acromegaly:

42
Pituitary, Bone, Thyroid, Heart, Testes, Brain, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Acromegaly:

20
Limb

Publications for Acromegaly

Articles related to Acromegaly:

(show top 50) (show all 3326)
# Title Authors Year
1
Biochemical following-up of treated acromegaly. Limitations of the current determinations of IGF-I and perspective. ( 30311754 )
2019
2
Pasireotide Responsiveness in Acromegaly Is Mainly Driven by Somatostatin Receptor Subtype 2 Expression. ( 30346538 )
2019
3
Correction to: Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study. ( 30382552 )
2019
4
Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature. ( 30397873 )
2019
5
Postoperative use of somatostatin analogs and mortality in patients with acromegaly. ( 30400068 )
2019
6
Is GH nadir during OGTT a reliable test for diagnosis of acromegaly in patients with abnormal glucose metabolism? ( 30415402 )
2019
7
Evaluation of the natural course of thyroid nodules in patients with acromegaly. ( 30430336 )
2019
8
Long-term management and postmortem examination in a diabetic cat with acromegaly treated with two courses of radiation therapy. ( 30449819 )
2019
9
Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy. ( 30474822 )
2019
10
Sleep apnea and cardiovascular complications of the acromegaly. Response to the medical treatment. ( 30482010 )
2019
11
Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI. ( 30506213 )
2019
12
Precision medicine in the treatment of acromegaly. ( 30531695 )
2019
13
Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study. ( 30535537 )
2019
14
Hypertension is Common in Patients with Newly Diagnosed Acromegaly and is Independently Associated with Renal Resistive Index. ( 30535798 )
2019
15
Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. ( 30566903 )
2019
16
Surgical-pharmacological interactions in the treatment of acromegaly. ( 30595057 )
2019
17
Ectopic acromegaly due to growth hormone-releasing hormone producing bronchial carcinoid causing somatotroph hyperplasia and partial pituitary insufficiency. ( 30608060 )
2019
18
How to Position Pasireotide LAR Treatment in Acromegaly. ( 30608534 )
2019
19
Daily life, needs and expectations of patients with acromegaly in France: An on-line survey. ( 30612694 )
2019
20
A registry of acromegaly patients and one year following up in Taiwan. ( 30612883 )
2019
21
Pregnancy in Acromegaly is safe and is associated with improvements in GH/IGF-1 concentrations. ( 30620709 )
2019
22
AcroVoice: eliciting the patients' perspective on acromegaly disease activity. ( 30627944 )
2019
23
Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly. ( 30640713 )
2019
24
Elastography detected solid organ stiffness increased in patients with acromegaly. ( 30653179 )
2019
25
Executive functioning and quality of life in acromegaly. ( 30655710 )
2019
26
PREDICTIVE MARKERS FOR POSTSURGICAL MEDICAL MANAGEMENT OF ACROMEGALY: A SYSTEMATIC REVIEW AND CONSENSUS TREATMENT GUIDELINE. ( 30657362 )
2019
27
An update on clinical care for pregnant women with acromegaly. ( 30696300 )
2019
28
Mutations in GPR101 as a potential cause of X-linked acrogigantism and acromegaly. ( 30711029 )
2019
29
Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles. ( 30718563 )
2019
30
Acromegaly in the era of precision medicine. ( 30732428 )
2019
31
Acromegaly associated with GIST, non-small cell lung carcinoma, clear cell renal carcinoma, multiple myeloma, medulla oblongata tumour, adrenal adenoma, and follicular thyroid nodules. ( 30742299 )
2019
32
The effect of disease activity on thyroid nodules in patients with acromegaly. ( 30745501 )
2019
33
Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study. ( 30756345 )
2019
34
Evidence of Pituitary Tumor and Acromegaly in an Ancient Egyptian Mummy Head. ( 30763964 )
2019
35
First report on persistent remission of acromegaly after withdrawal of long-term pegvisomant monotherapy. ( 30772778 )
2019
36
ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly. ( 30773338 )
2019
37
Outcomes after Gamma knife Stereotactic Radiosurgery in pediatric patients with Cushing's disease or Acromegaly: A multi-institutional study. ( 30790739 )
2019
38
AcroVoice: the controversial values in reflecting acromegaly disease activity. ( 30796718 )
2019
39
Acromegaly can be cured by first-line pasireotide treatment? ( 30798431 )
2019
40
Soluble delta-like 1 homolog decreases in patients with acromegaly following pituitary surgery: A potential mediator of adipogenesis suppression by growth hormone? ( 30818110 )
2019
41
The combination of acromegaly and Klinefelter syndrome in one patient. ( 30823838 )
2019
42
Pretreatment with somatostatin analogs does not affect the anesthesiologic management of patients with acromegaly. ( 30826981 )
2019
43
Dental Implant Therapy in a Patient with Acromegaly: A Clinical Report. ( 30830701 )
2019
44
The real costs of acromegaly: analysis of different therapies. ( 30843180 )
2019
45
Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology. ( 30843181 )
2019
46
E-cadherin expression is associated with somatostatin analogue response in acromegaly. ( 30843342 )
2019
47
AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients. ( 30851160 )
2019
48
A case of acromegaly caused by Rathke's cleft cyst mimicking a plurihormonal pituitary adenoma. ( 30862574 )
2019
49
HIGHER GROWTH HORMONE LEVELS ARE ASSOCIATED WITH ERECTILE DYSFUNCTION IN MALE PATIENTS WITH ACROMEGALY. ( 30865541 )
2019
50
Pegvisomant improves Glucose Metabolism in Acromegaly: a meta-analysis of prospective interventional studies. ( 30869797 )
2019

Variations for Acromegaly

ClinVar genetic disease variations for Acromegaly:

6 (show top 50) (show all 145)
# Gene Variation Type Significance SNP ID Assembly Location
1 AIP NM_003977.3(AIP): c.910C> T (p.Arg304Ter) single nucleotide variant Pathogenic rs104894195 GRCh38 Chromosome 11, 67490910: 67490910
2 AIP NM_003977.3(AIP): c.910C> T (p.Arg304Ter) single nucleotide variant Pathogenic rs104894195 GRCh37 Chromosome 11, 67258381: 67258381
3 AIP NM_003977.3(AIP): c.469-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs267606555 GRCh38 Chromosome 11, 67490037: 67490037
4 AIP NM_003977.3(AIP): c.40C> T (p.Gln14Ter) single nucleotide variant Pathogenic rs104894194 GRCh37 Chromosome 11, 67250669: 67250669
5 AIP NM_003977.3(AIP): c.40C> T (p.Gln14Ter) single nucleotide variant Pathogenic rs104894194 GRCh38 Chromosome 11, 67483198: 67483198
6 AIP NM_003977.3(AIP): c.469-1G> A single nucleotide variant Pathogenic/Likely pathogenic rs267606555 GRCh37 Chromosome 11, 67257508: 67257508
7 AIP NM_003977.3(AIP): c.66_71delAGGAGA (p.Gly23_Glu24del) deletion Pathogenic/Likely pathogenic rs267606567 GRCh37 Chromosome 11, 67250695: 67250700
8 AIP NM_003977.3(AIP): c.66_71delAGGAGA (p.Gly23_Glu24del) deletion Pathogenic/Likely pathogenic rs267606567 GRCh38 Chromosome 11, 67483224: 67483229
9 AIP NM_003977.3(AIP): c.824dup (p.His275Glnfs) duplication Pathogenic/Likely pathogenic rs267606580 GRCh37 Chromosome 11, 67258295: 67258295
10 AIP NM_003977.3(AIP): c.824dup (p.His275Glnfs) duplication Pathogenic/Likely pathogenic rs267606580 GRCh38 Chromosome 11, 67490824: 67490824
11 AIP NM_003977.3(AIP): c.542delT (p.Ile182Serfs) deletion Pathogenic/Likely pathogenic rs267606559 GRCh37 Chromosome 11, 67257582: 67257582
12 AIP NM_003977.3(AIP): c.542delT (p.Ile182Serfs) deletion Pathogenic/Likely pathogenic rs267606559 GRCh38 Chromosome 11, 67490111: 67490111
13 AIP NM_003977.3(AIP): c.804C> A (p.Tyr268Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908356 GRCh37 Chromosome 11, 67258275: 67258275
14 AIP NM_003977.3(AIP): c.804C> A (p.Tyr268Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908356 GRCh38 Chromosome 11, 67490804: 67490804
15 AIP NM_003977.3(AIP): c.911G> A (p.Arg304Gln) single nucleotide variant drug response rs104894190 GRCh37 Chromosome 11, 67258382: 67258382
16 AIP NM_003977.3(AIP): c.911G> A (p.Arg304Gln) single nucleotide variant drug response rs104894190 GRCh38 Chromosome 11, 67490911: 67490911
17 AIP NM_003977.3(AIP): c.64C> T (p.Arg22Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908357 GRCh37 Chromosome 11, 67250693: 67250693
18 AIP NM_003977.3(AIP): c.64C> T (p.Arg22Ter) single nucleotide variant Pathogenic/Likely pathogenic rs121908357 GRCh38 Chromosome 11, 67483222: 67483222
19 AIP NM_003977.2(AIP): c.-1212_279+578del deletion Likely pathogenic GRCh37 Chromosome 11, 67249418: 67255234
20 AIP NM_003977.2(AIP): c.-1212_279+578del deletion Likely pathogenic GRCh38 Chromosome 11, 67481947: 67487763
21 AIP NM_003977.3(AIP): c.-5G> C single nucleotide variant Likely benign rs267606562 GRCh37 Chromosome 11, 67250625: 67250625
22 AIP NM_003977.3(AIP): c.-5G> C single nucleotide variant Likely benign rs267606562 GRCh38 Chromosome 11, 67483154: 67483154
23 AIP NM_003977.2(AIP): c.(?_1)_(*_?)del deletion Likely pathogenic
24 AIP NM_003977.3(AIP): c.100-1025_279+357del1562 deletion Likely pathogenic GRCh37 Chromosome 11, 67253452: 67255013
25 AIP NM_003977.3(AIP): c.100-1025_279+357del1562 deletion Likely pathogenic GRCh38 Chromosome 11, 67485981: 67487542
26 AIP NM_003977.3(AIP): c.135C> T (p.Asp45=) single nucleotide variant Likely benign rs181969066 GRCh37 Chromosome 11, 67254512: 67254512
27 AIP NM_003977.3(AIP): c.135C> T (p.Asp45=) single nucleotide variant Likely benign rs181969066 GRCh38 Chromosome 11, 67487041: 67487041
28 AIP NM_003977.3(AIP): c.138_161del24 (p.Gly47_Arg54del) deletion Likely pathogenic rs267606537 GRCh37 Chromosome 11, 67254515: 67254538
29 AIP NM_003977.3(AIP): c.138_161del24 (p.Gly47_Arg54del) deletion Likely pathogenic rs267606537 GRCh38 Chromosome 11, 67487044: 67487067
30 AIP NM_003977.3(AIP): c.145G> A (p.Val49Met) single nucleotide variant Conflicting interpretations of pathogenicity rs1063385 GRCh37 Chromosome 11, 67254522: 67254522
31 AIP NM_003977.3(AIP): c.145G> A (p.Val49Met) single nucleotide variant Conflicting interpretations of pathogenicity rs1063385 GRCh38 Chromosome 11, 67487051: 67487051
32 AIP NM_003977.3(AIP): c.166C> A (p.Arg56Ser) single nucleotide variant Likely pathogenic rs267606538 GRCh37 Chromosome 11, 67254543: 67254543
33 AIP NM_003977.3(AIP): c.166C> A (p.Arg56Ser) single nucleotide variant Likely pathogenic rs267606538 GRCh38 Chromosome 11, 67487072: 67487072
34 AIP NM_003977.3(AIP): c.174G> C (p.Lys58Asn) single nucleotide variant Uncertain significance rs267606539 GRCh37 Chromosome 11, 67254551: 67254551
35 AIP NM_003977.3(AIP): c.174G> C (p.Lys58Asn) single nucleotide variant Uncertain significance rs267606539 GRCh38 Chromosome 11, 67487080: 67487080
36 AIP NM_003977.3(AIP): c.241C> T (p.Arg81Ter) single nucleotide variant Pathogenic rs267606541 GRCh37 Chromosome 11, 67254618: 67254618
37 AIP NM_003977.3(AIP): c.241C> T (p.Arg81Ter) single nucleotide variant Pathogenic rs267606541 GRCh38 Chromosome 11, 67487147: 67487147
38 AIP NM_003977.3(AIP): c.244_248delGAAGG (p.Glu82Glyfs) deletion Likely pathogenic rs267606542 GRCh37 Chromosome 11, 67254621: 67254625
39 AIP NM_003977.3(AIP): c.244_248delGAAGG (p.Glu82Glyfs) deletion Likely pathogenic rs267606542 GRCh38 Chromosome 11, 67487150: 67487154
40 AIP NM_003977.3(AIP): c.249G> T (p.Gly83=) single nucleotide variant Likely pathogenic rs104895072 GRCh37 Chromosome 11, 67254626: 67254626
41 AIP NM_003977.3(AIP): c.249G> T (p.Gly83=) single nucleotide variant Likely pathogenic rs104895072 GRCh38 Chromosome 11, 67487155: 67487155
42 AIP NM_003977.3(AIP): c.250G> A (p.Glu84Lys) single nucleotide variant Likely pathogenic rs267606543 GRCh37 Chromosome 11, 67254627: 67254627
43 AIP NM_003977.3(AIP): c.250G> A (p.Glu84Lys) single nucleotide variant Likely pathogenic rs267606543 GRCh38 Chromosome 11, 67487156: 67487156
44 AIP NM_003977.3(AIP): c.280-1G> A single nucleotide variant Likely pathogenic rs267606544 GRCh37 Chromosome 11, 67256737: 67256737
45 AIP NM_003977.3(AIP): c.280-1G> A single nucleotide variant Likely pathogenic rs267606544 GRCh38 Chromosome 11, 67489266: 67489266
46 AIP NM_003977.3(AIP): c.286_287delGT (p.Val96Profs) deletion Likely pathogenic rs267606545 GRCh37 Chromosome 11, 67256744: 67256745
47 AIP NM_003977.3(AIP): c.286_287delGT (p.Val96Profs) deletion Likely pathogenic rs267606545 GRCh38 Chromosome 11, 67489273: 67489274
48 AIP NM_003977.3(AIP): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs267606546 GRCh37 Chromosome 11, 67250631: 67250631
49 AIP NM_003977.3(AIP): c.2T> C (p.Met1Thr) single nucleotide variant Likely pathogenic rs267606546 GRCh38 Chromosome 11, 67483160: 67483160
50 AIP NM_003977.3(AIP): c.308A> G (p.Lys103Arg) single nucleotide variant Likely pathogenic rs267606548 GRCh37 Chromosome 11, 67256766: 67256766

Expression for Acromegaly

Search GEO for disease gene expression data for Acromegaly.

Pathways for Acromegaly

Pathways related to Acromegaly according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 GHRH GHRL GNAS IGF1 IGF2 INS
2
Show member pathways
13.65 GH1 GHRL IGF1 IGF2 IGFBP1 IGFBP3
3
Show member pathways
13.36 GH1 GHR GHRH GNAS IGF1 IGF2
4
Show member pathways
12.87 GH1 GHRH GNAS IGF1 IGF2 INS
5
Show member pathways
12.75 GH1 GHR GNAS IGF1 IGF2 INS
6
Show member pathways
12.73 GH1 GHR IGF1 IGFBP3 INS
7
Show member pathways
12.68 GH1 GHR GHRH GHRL GNAS POMC
8
Show member pathways
12.22 IGF1 IGF2 IGFBP1 IGFBP3
9 12.05 GHRL GNAS SSTR1 SSTR2 SSTR5
10
Show member pathways
11.91 GH1 GHRL IGF1 INS POMC
11 11.77 IGF1 IGFBP3 INS
12 11.49 GH1 GHRH GNAS IGF1 IGF2
13 11.4 IGF1 IGF2 INS
14 11.32 GNAS IGF1 INS
15 11.27 GH1 GHR IGF1 IGF2
16
Show member pathways
11.22 GH1 GHR PRL
17 10.85 GH1 GHRH GNAS IGF1 IGF2
18 10.58 IGF1 IGF2 IGFBP1 IGFBP3

GO Terms for Acromegaly

Cellular components related to Acromegaly according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 GH1 GHR GHRH GHRL IGF1 IGF2
2 endoplasmic reticulum lumen GO:0005788 9.72 GHRL IGFBP1 IGFBP3 INS MEN1
3 extracellular region GO:0005576 9.47 GH1 GHR GHRH GHRL GNAS IGF1
4 secretory granule GO:0030141 9.43 POMC TRH
5 insulin-like growth factor ternary complex GO:0042567 9.4 IGF1 IGFBP3
6 insulin-like growth factor binding protein complex GO:0016942 9.37 IGF1 IGFBP3
7 endosome lumen GO:0031904 9.33 GH1 INS PRL
8 growth hormone receptor complex GO:0070195 9.26 GH1 GHR

Biological processes related to Acromegaly according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.95 IGFBP3 MEN1 SST SSTR1 SSTR2 SSTR5
2 G protein-coupled receptor signaling pathway GO:0007186 9.9 GHRH GHRL GNAS GPR101 INS POMC
3 cell-cell signaling GO:0007267 9.89 GHRH INS POMC SST TRH
4 positive regulation of MAPK cascade GO:0043410 9.87 IGF1 IGF2 IGFBP3 INS
5 neuropeptide signaling pathway GO:0007218 9.83 POMC SSTR1 SSTR2 SSTR5
6 insulin receptor signaling pathway GO:0008286 9.82 IGF2 IGFBP1 INS
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.82 GH1 IGF1 INS
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 GH1 GHR IGF1
9 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.8 SSTR1 SSTR2 SSTR5
10 glucose metabolic process GO:0006006 9.8 GHRL IGF2 INS
11 cellular protein metabolic process GO:0044267 9.8 IGF1 IGF2 IGFBP1 IGFBP3 INS MEN1
12 response to nutrient levels GO:0031667 9.79 GH1 GHRL PRL
13 hormone-mediated signaling pathway GO:0009755 9.77 GHR GHRL TRH
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.76 GH1 GHR IGF1 IGF2
15 regulation of multicellular organism growth GO:0040014 9.72 GHR IGF1 PRL
16 positive regulation of mitotic nuclear division GO:0045840 9.71 IGF1 IGF2 INS
17 positive regulation of JAK-STAT cascade GO:0046427 9.69 GH1 GHR PRL
18 positive regulation of insulin receptor signaling pathway GO:0046628 9.67 IGF2 INS
19 insulin-like growth factor receptor signaling pathway GO:0048009 9.66 GHR IGF1
20 growth hormone receptor signaling pathway GO:0060396 9.65 GH1 GHR
21 positive regulation of growth GO:0045927 9.65 GH1 GHRL
22 positive regulation of growth hormone secretion GO:0060124 9.64 GHRH GHRL
23 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.62 GH1 GHRH IGF1 IGFBP3
24 growth hormone secretion GO:0030252 9.61 GHRH GHRL
25 negative regulation of feeding behavior GO:2000252 9.61 INS TRH
26 positive regulation of glycogen biosynthetic process GO:0045725 9.61 IGF1 IGF2 INS
27 positive regulation of insulin secretion GO:0032024 9.58 GHRL TRH
28 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 GH1 GHR PRL
29 somatostatin signaling pathway GO:0038170 9.54 SSTR1 SSTR2 SSTR5
30 positive regulation of multicellular organism growth GO:0040018 9.35 GH1 GHR GHRH GHRL IGF2
31 regulation of signaling receptor activity GO:0010469 9.32 GH1 GHRH GHRL IGF1 IGF2 INS
32 positive regulation of circadian sleep/wake cycle, non-REM sleep GO:0046010 9.29 GHRL
33 positive regulation of lactation GO:1903489 9.26 PRL
34 signal transduction GO:0007165 10.23 GNAS GPR101 IGF1 IGFBP1 POMC SSTR1
35 positive regulation of cell proliferation GO:0008284 10.06 GHRH IGF1 IGF2 INS PRL

Molecular functions related to Acromegaly according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor binding GO:0001664 9.65 GHRL GNAS POMC
2 growth factor binding GO:0019838 9.61 GHR IGFBP1 IGFBP3
3 insulin receptor binding GO:0005158 9.5 IGF1 IGF2 INS
4 insulin-like growth factor I binding GO:0031994 9.49 IGFBP1 IGFBP3
5 insulin-like growth factor II binding GO:0031995 9.46 IGFBP1 IGFBP3
6 neuropeptide binding GO:0042923 9.43 SSTR1 SSTR2 SSTR5
7 growth hormone-releasing hormone activity GO:0016608 9.4 GHRH GHRL
8 prolactin receptor binding GO:0005148 9.37 GH1 PRL
9 somatostatin receptor activity GO:0004994 9.33 SSTR1 SSTR2 SSTR5
10 hormone activity GO:0005179 9.28 GH1 GHRL IGF1 IGF2 INS POMC
11 insulin-like growth factor receptor binding GO:0005159 9.26 GNAS IGF1 IGF2 INS

Sources for Acromegaly

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....